Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

This study has been terminated.
Sponsor:
Information provided by:
Mirati Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00358982
First received: July 31, 2006
Last updated: January 6, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2009
  Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
No publications provided by Mirati Therapeutics Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):